Contract
Scientist - Computational Biology
Multiple Teams
Posted on 8/22/2025
Altos Labs
501-1,000 employees
Biotech startup advancing cellular rejuvenation therapies
Compensation Overview
$78 - $121/hr
San Francisco, CA, USA + 1 more
More locations: San Diego, CA, USA
In Person
 Biology & Biotech (2) |
|---|
| , |
- PhD in Statistical Genetics, Data Science, or Computer Science
- 3+ years experience in an academic postdoctoral or industry research setting
- Familiarity with data from genetic association testing (e.g. GWAS, rare variant analysis)
- Experience with large nation-scale biobank data (e.g. UK Biobank), understanding of genetic, omics, and disease ontology data
- Proficiency in relevant programming languages (Python, R, AI/ML etc.) and best practices in reproducible data analysis
- Track record of publications in peer-reviewed journals
- Excellent collaboration skills and ability to thrive in the highly collaborative environment across Altos
- Team player and effective communicator
- Harvest and analyze data from genetic association testing to dissect the molecular and cellular basis of disease.
- Conduct computational research related to areas such as chronic disease risk and modifiers thereof by integrating data from multiple biologic sources (i.e. genetics, molecular biomarkers, phenotyping)
- Enable scalable research efforts by supporting the ingestion, storage, harmonization, QC, and access of large data resources
- Confer with information technology, computational biology, and machine learning specialists to enable and streamline genetic data analysis.
- Contribute to a team culture that promotes continuous improvement, ownership, professional growth, and inclusion
- Hands-on experience with the UK Biobank Research Access Platform (RAP) or similar biobank IDE.
- History of generating reproducible workflows or pipelines for bioinformatic data analysis
- Prior experience with GWAS summary statistics harmonization and QC, fine-mapping, colocalization, Mendelian Randomization
Altos Labs focuses on cell rejuvenation research to restore cellular health and resilience, with the aim of reversing diseases, injuries, and disabilities by programming cells to resist stressors that cause illness. It advances biotech R&D in cellular rejuvenation, producing treatments that can be commercialized for healthcare providers or patients and likely collaborates with research institutions and pharma partners. Unlike purely diagnostic firms, Altos Labs centers on developing breakthrough cellular therapies and regenerative strategies grounded in research, seeking to improve long-term health outcomes. Its goal is to translate cellular rejuvenation science into practical treatments that extend healthspan and reverse disease processes.
Company Size
501-1,000
Company Stage
Early VC
Total Funding
$3.3B
Headquarters
Los Altos, California
Founded
2021
Simplify's Take
What believers are saying
- Appointed Dr. Joan Mannick as CMO to launch clinical trials.
- $3 billion funding from Jeff Bezos enables rapid R&D scaling.
- Acquired Stanford-rooted biotech to bolster aging-stopping pipeline.
What critics are saying
- Calico Labs advances AI-driven programs, eroding first-mover edge.
- FDA rejection of Rejuvenate Bio's therapy heightens scrutiny.
- Yamanaka toxicity in primate trials forces reprogramming redesign.
What makes Altos Labs unique
- Altos Labs pioneers cellular rejuvenation programming using Yamanaka factors.
- Operates Institutes in San Francisco, San Diego, and Cambridge, UK.
- Focuses on reversing disease via partial reprogramming, not full iPSCs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 1%2 year growth
↑ 1%Longevity biotech giant Altos Labs has appointed Dr Joan Mannick as its Chief Medical Officer and head of product development, signaling a shift toward advancing clinical programs based on the company's cellular rejuvenation technology.
Altos Labs, backed by $3 billion from Jeff Bezos and others, has snagged a small Peninsula company focused on one approach to stopping aging
In London, Altos recently launched its inaugural Margarita Masters competition for bartenders, with the hope of taking it nationwide in the future.
«Per uno scienziato Elon Musk ha senz’altro meno appeal di un Premio Nobel». Se poi i Nobel sono quattro, tutti seduti nel board of directors della startup per cui lavori, potremmo dire non esserci partita. Tra questi, ad esempio, Jennifer Doudna, che ha vinto grazie al lavoro sull’editing genetico Crispr nel 2020. Simone Bianco, employee numero 27 di Altos Labs con sede a San Francisco, è Principal Investigator e Director of Computational Biology in quella che lui preferisce definire una venture, non una startup. Nel corso dell’intervista gli abbiamo chiesto di Musk e dei suoi piani per salvare l’umanità, anche con Neuralink, ma la discussione ha rapidamente virato verso altre figure, più specializzate nella materia in questione. Altos Labs, dunque
If technology allowed humanity to live forever in the future, would you take the ticket? We asked our readers recently and were surprised to see the balance tilt towards “No” (60% of respondents). One answer was hidden in a comment from one of our readers – they would want to live forever, yet only if they stayed young. Among others, living long worries people as it is associated with getting old and suffering from various diseases.Yet if technology allows us to extend our life spans it will also likely improve our health spans. According to demographers, children today have a better chance of living up to 100 years old than ever before. But their lives won’t be just longer, they will also benefit from day-to-day technological advances aimed at improving their well-being, preventing diseases, and keeping their minds and bodies in shape.Slowing aging presents an economic opportunity, too. In the US, an estimate shows that just one to two years increase in life expectancy are worth between $7 trillion and $38 trillion